Journal Mobile Options
Table of Contents
Vol. 78, No. 1, 2008
Issue release date: November 2008
Section title: Original Paper
Digestion 2008;78:34–38
(DOI:10.1159/000156702)

Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma

Graf H. · Jüngst C. · Straub G. · Dogan S. · Hoffmann R.-T. · Jakobs T. · Reiser M. · Waggershauser T. · Helmberger T. · Walter A. · Walli A. · Seidel D. · Göke B. · Jüngst D.
Departments of aMedicine II, bRadiology and cClinical Chemistry, Klinikum Grosshadern, Ludwig Maximilian University, dDepartment of Radiology, Klinikum Bogenhausen, and eDepartment of Surgery, Klinikum der Barmherzigen Brüder, Munich, and fDepartment of Internal Medicine, Klinikum Landshut, Landshut, Germany; gDivision of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/30/2008
Accepted: 8/6/2008
Published online: 9/17/2008
Issue release date: November 2008

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: http://www.karger.com/DIG

Abstract

Background/Aims: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been shown to inhibit growth and to induce apoptosis in human hepatocellular carcinoma (HCC) cells. However, the potential benefit of pravastatin in HCC patients has still not been characterized, which prompted us to test the efficacy of pravastatin in patients with advanced HCC. Methods: We investigated prospectively a cohort of 183 HCC patients who had been selected for palliative treatment by transarterial chemoembolization (TACE). Fifty-two patients received TACE combined with pravastatin (20–40 mg/day) and 131 patients received chemoembolization alone. Six independent predictors of survival according to the Vienna survival model for HCC were equally distributed in both groups. Results: During the observation period of up to 5 years, 31 (23.7%) out of 131 patients treated by TACE alone and 19 (36.5%) out of 52 patients treated by TACE and pravastatin survived. Median survival was significantly longer in HCC patients treated by TACE and pravastatin (20.9 months, 95% CI 15.5–26.3, p = 0.003) than in HCC patients treated by TACE alone (12.0 months, 95% CI 10.3–13.7). Conclusion: Combined treatment of chemoembolization and pravastatin improves survival of patients with advanced HCC in comparison to patients receiving chemoembolization alone.


  

Author Contacts

Dieter Jüngst, MD
Department of Medicine II, Klinikum Grosshadern
Ludwig Maximilian University, Marchioninistrasse 15
DE–81377 München (Germany), Tel. +49 89 7095 2376, Fax +49 89 7095 5374
E-Mail Dieter.Juengst@med.uni-muenchen.de

  

Article Information

Received: April 30, 2008
Accepted: August 6, 2008
Published online: September 17, 2008
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 1, Number of References : 36

  

Publication Details

Digestion (International Journal of Gastroenterology)

Vol. 78, No. 1, Year 2008 (Cover Date: November 2008)

Journal Editor: Beglinger C. (Basel), Göke B. (Munich)
ISSN: 0012–2823 (Print), eISSN: 1421–9867 (Online)

For additional information: http://www.karger.com/DIG


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/30/2008
Accepted: 8/6/2008
Published online: 9/17/2008
Issue release date: November 2008

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: http://www.karger.com/DIG


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.